Capricor Therapeutics (CAPR) Net Income towards Common Stockholders (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Net Income towards Common Stockholders of -$33.9 million for Q1 2026, down 39.15% year-over-year from -$55.8 million in Q1 2025, and down 13.27% quarter-over-quarter from -$30.0 million in Q4 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$33.9 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 39.15% year-over-year to -$33.9 million; the TTM figure through Mar 2026 stood at -$212.8 million (down 15.09% YoY), while the FY2025 annual figure was -$105.0 million, down 159.58% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$33.9 million, down from -$30.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$561514.0 in Q4 2023, with the low at -$131.1 million in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$23.1 million (2024), against an average of -$31.2 million.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 93.12% in 2023, then slumped 1133.65% in 2024.
- Capricor Therapeutics' Net Income towards Common Stockholders stood at -$8.2 million in 2022, then surged by 93.12% to -$561514.0 in 2023, then slumped by 1027.8% to -$6.3 million in 2024, then slumped by 373.17% to -$30.0 million in 2025, then slipped by 13.27% to -$33.9 million in 2026.
- Business Quant data shows CAPR's Net Income towards Common Stockholders at -$33.9 million in Q1 2026, -$30.0 million in Q4 2025, and -$60.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | -40.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.73 Mn |
| Mar 31, 2026 | -33.94 Mn |
| Dec 31, 2025 | -27.13 Mn |
| Sep 30, 2025 | -24.57 Mn |
| Jun 30, 2025 | -25.91 Mn |
| Mar 31, 2025 | -24.39 Mn |
| Dec 31, 2024 | -7.01 Mn |
| Sep 30, 2024 | -12.56 Mn |
| Jun 30, 2024 | -11.74 Mn |
| Mar 31, 2024 | -10.19 Mn |
| Dec 31, 2023 | -829,093.00 |
| Sep 30, 2023 | -6.39 Mn |
| Jun 30, 2023 | -7.66 Mn |
| Mar 31, 2023 | -8.19 Mn |
| Dec 31, 2022 | -7.69 Mn |
| Sep 30, 2022 | -6.37 Mn |
| Jun 30, 2022 | -7.30 Mn |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | -6.36 Mn |
| Sep 30, 2021 | -4.30 Mn |